Download Free Electronic Document

FormatFile SizeNotes
PDF file 0.2 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

This paper evaluates the causes of the unmet need for investment in drugs targeting central nervous system diseases and discusses policy solutions to better align drug development with untreated disease burden. The authors' analysis suggests that current market forces are stacking the deck against development of drugs for common CNS disorders, as the expected returns on investment are lower and more uncertain than those for, say, targeted cancer drugs. They propose several policy changes that could steer investment into drugs for these "new neglected diseases" by reducing development cost and uncertainty and increasing expected revenue.

The research underlying this paper was conducted in RAND Health, a division of the RAND Corporation.

This report is part of the RAND Corporation perspective series. RAND perspectives present informed perspective on a timely topic that address the challenges facing the public and private sectors. All RAND perspectives undergo rigorous peer review to ensure high standards for research quality and objectivity.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.